Please login to the form below

Not currently logged in
Email:
Password:

MedImmune

This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Teva close gap on rivals with NGF pain drug

Regeneron and Teva close gap on rivals with NGF pain drug

NGF inhibitors have had a chequered history, with a long list of discontinued candidates, mainly due to side effect issues, from the likes of AstraZeneca/Medimmune and AbbVie, amongst others.

Latest news

More from news
Approximately 15 fully matching, plus 98 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    This physical environment gives us an opportunity to work in a different way, ”said Jane Osbourn, the company’s site lead and vice-president for research and development at MedImmune, its

  • Deal Watch March 2017 Deal Watch March 2017

    Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory

  • Deal Watch October 2016 Deal Watch October 2016

    Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).

  • Deal Watch February 2016 Deal Watch February 2016

    We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/

  • Pharma deals in August 2015 Pharma deals in August 2015

    MedImmune has paid $27.5m upfront, with a further $700m in milestones and double digit tiered royalties. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for cervical and head &neck cancer.

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    AZ and Medimmune bolsters immuno-oncology leadership. Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. ... AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria,

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    AstraZeneca appoints head of oncology. Dr Jamie Freedman joins from AZ subsidiary MedImmune. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Envigo appoints Patricia Henahan as chief financial officer Envigo appoints Patricia Henahan as chief financial officer

    Henahan brings 15 years of financial experience in the life science sector, including senior leadership roles at AstraZeneca, Eli Lilly and MedImmune.

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    Sanofi appoints Dr Yong-Jun Liu as head of research. He brings experience from MedImmune and the Baylor Research Institute. ... In January 2014, Dr Liu was appointed head of research at MedImmune, his most recent position.

More from appointments
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics